Basel, Switzerland

David Edmonds

This inventor holds 10 USPTO granted patents and 11 published patent applications. Top assignee: Pfizer Corporation. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Edmonds. Retrieved from https://idiyas.com/inventor/david-edmonds

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 10 

% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Location History:

  • Basel, CH (2022 - 2024)
  • Riehen, CH (2024)

Company Filing History:


Years Active: 2022-2026

Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovations of David Edmonds - A Visionary Inventor from Basel

Introduction

David Edmonds, an esteemed inventor based in Basel, Switzerland, has made significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of seven patents, he has focused on the development of GLP-1 receptor agonists, which have potential therapeutic applications in treating certain medical conditions.

Latest Patents

Among his latest innovations, David Edmonds has created patents that detail the use of 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists. These patents include processes for synthesizing these compounds and methods for administering them to mammals in need, highlighting the potential impact on improving patient outcomes in specific health scenarios.

Career Highlights

Throughout his career, David has consistently pushed the boundaries of medicinal chemistry. His role at Pfizer Corporation has allowed him to collaborate on groundbreaking projects that aim to improve the lives of many through innovative pharmaceutical solutions.

Collaborations

David Edmonds values collaboration and has worked closely with notable colleagues such as David Andrew Griffith and Scott William Bagley. These partnerships have led to collective advancements in their shared fields, fostering a rich environment of innovation and discovery.

Conclusion

In summary, David Edmonds stands out as a leading inventor in Basel, with a keen focus on GLP-1 receptor agonists. His impressive patent portfolio and collaborations with fellow inventors reflect his commitment to advancing medical research. As he continues to develop new solutions, the impact of his inventions will likely resonate in the pharmaceutical industry for years to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…